Profile
Mikio Kawahara currently works at AccuRna, Inc., as Director from 2017, Braizon Therapeutics, Inc., as Outside Director from 2018, Adriakaim, Inc., as Outside Director from 2020, Fimecs, Inc., as Outside Director from 2020, and UTokyo Innovation Platform Co.,Ltd., as Partner and Chief Investment Officer from 2016.
Mikio Kawahara active positions
| Companies | Position | Start |
|---|---|---|
AccuRna, Inc.
AccuRna, Inc. BiotechnologyHealth Technology Researches and develops nucleic acid-based drugs using drug delivery system technologies | Director/Board Member | 30/11/2017 |
Fimecs, Inc.
Fimecs, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of new drugs whose mechanism is induction of proteolysis | Director/Board Member | 31/12/2019 |
UTokyo Innovation Platform Co.,Ltd.
UTokyo Innovation Platform Co.,Ltd. Investment ManagersFinance UTokyo IPC is an active manger which targets companies of University of Tokyo origin. It provides equity for pre-seed, seed and early-stages capital requirements. | Chief Investment Officer | 31/12/2015 |
Braizon Therapeutics, Inc.
Braizon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing drugs | Director/Board Member | 31/07/2018 |
Adriakaim, Inc.
Adriakaim, Inc. Medical SpecialtiesHealth Technology Manufactures and sells medical and health-related equipment & provides management and technology strategy consulting services | Director/Board Member | 30/04/2020 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
AccuRna, Inc.
AccuRna, Inc. BiotechnologyHealth Technology Researches and develops nucleic acid-based drugs using drug delivery system technologies | Health Technology |
UTokyo Innovation Platform Co.,Ltd.
UTokyo Innovation Platform Co.,Ltd. Investment ManagersFinance UTokyo IPC is an active manger which targets companies of University of Tokyo origin. It provides equity for pre-seed, seed and early-stages capital requirements. | Finance |
Braizon Therapeutics, Inc.
Braizon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing drugs | Commercial Services |
Adriakaim, Inc.
Adriakaim, Inc. Medical SpecialtiesHealth Technology Manufactures and sells medical and health-related equipment & provides management and technology strategy consulting services | Health Technology |
Fimecs, Inc.
Fimecs, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of new drugs whose mechanism is induction of proteolysis | Commercial Services |
- Stock Market
- Insiders
- Mikio Kawahara
















